Trial Profile
Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 11 Mar 2013 Actual end date changed from Jan 2010 to May 2010 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual patient number (599) added as reported by ClinicalTrials.gov.